The Access to Medicine Index, a ranking of pharmaceutical companies' work to distribute medications to low- and middle-income countries, just named Johnson & Johnson #3 on its biennial list, underscoring the company's deep history of ensuring people in underserved communities receive the treatments they need.
A potential COVID-19 vaccine. Passionate efforts toward achieving racial and social justice. Smarter, more sustainable product packaging. These are just a few of the resolutions company change makers are aiming to bring to light this year—and they're already hard at work on them.
With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
From epidemic masks that the company introduced during the Spanish flu pandemic to work it's doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.
The company is proud to have made the list for the second year in a row. From its work on an Ebola vaccine—and an investigational COVID-19 vaccine—to collaboration taking place across its Johnson & Johnson Innovation centers, we take a look at the innovative spirit that permeates the company's culture.
The clinical trial has completed full immunizations of the company's investigational HIV vaccine regimen. Learn what this means for the future of fighting the disease—and also for the creation of a potential vaccine for COVID-19.
As the European Commission grants Marketing Authorization forthe company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
The coronavirus has made headlines as it has spread from China to other parts of the world. To help stop the global outbreak in its tracks, Johnson & Johnson is already hard at work on a potential preventive vaccine.
From a first-of-its-kind contact lens that darkens when exposed to bright light to the first donation of 500,000 doses of an Ebola vaccine, here are just some of the ways Johnson & Johnson helped change the trajectory of health for humanity this past year.
The company has committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to help protect citizens of the Democratic Republic of the Congo—the site of the world's second largest outbreak of the disease.